SARS CoV 2 News and Research

RSS

Lancet report highlights global failures of COVID-19 response, calls for strengthened multilateralism to eradicate pandemic

Widespread, global failures at multiple levels in the COVID-19 response led to millions of preventable deaths and reversed progress made towards the UN Sustainable Development Goals (SDGs) in many countries, according to a new Lancet COVID-19 Commission report.

14 Sep 2022

Defensosomes versus COVID-19

In a recent study published in the journal PLoS Biology, researchers investigated the role of angiotensin-converting enzyme 2 (ACE2)-containing defensive exosomes, or 'defensosomes' against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.

14 Sep 2022

High levels of mucosal antibodies in the airways reduce the risk of omicron infection

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three doses of the SARS-CoV-2 vaccine.

14 Sep 2022

SARS-CoV-2 RNA and antibody detection in infected mothers’ breast milk

In a recent study published in the Journal of Medical Virology, Italian researchers investigated the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ribonucleic acid (RNA) and antibodies (Abs) in the milk of breastfeeding mothers with SARS-CoV-2 infections.

14 Sep 2022

Customized bivalent mRNA COVID boosters protect against BA.5 Omicron variant

In a recent study posted to the bioRxiv* pre-print server, researchers from Washington University School of Medicine, Moderna, Inc, and the U.S. National Institutes of Health tested two bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines based on the messenger ribonucleic acid (mRNA) platform.

14 Sep 2022

Winners of the 2022 CURE-19 Research Pilot Grants announced

The Arnhold Institute for Global Health at the Icahn School of Medicine at Mount Sinai and NYC Health + Hospitals have announced the 2022 awardees of the CURE-19 Research Pilot Grants, an initiative to support collaborative, interdisciplinary COVID-19 research that will address both the pandemic and root causes of health disparities in New York City.

14 Sep 2022

STRATAGEM aims to provide new perspectives on multidrug-resistant solid tumors

Achieving a good efficacy of chemotherapy is one of the major challenges still unresolved in oncological patients. The main limitation to the efficacy of chemotherapy is the multidrug-resistant (MDR) phenotype, a multiple cross-resistance towards different anticancer drugs.

14 Sep 2022

U-M scientists give tips about how teachers can keep classrooms safe from COVID-19

Since the Centers for Disease Control and Prevention acknowledged SARS-CoV-2 was airborne in spring 2020, University of Michigan aerosol scientists Andrew Ault and Kerri Pratt have advised public school systems on how to mitigate the transmission of COVID-19 in the classroom.

14 Sep 2022

Interactions between SIRT5 and SARS-CoV-2 Nsp14 protein

In a new study, researchers investigated the interactions between sirtuin 5 (SIRT5) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nonstructural protein (Nsp14) protein.

14 Sep 2022

What is the impact of COVID-19 treatments targeting intracellular Neu1?

In a new study, researchers assessed the impact of targeting intracellular Neu1 on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

14 Sep 2022

Intranasal administration of liposomes displaying SARS-CoV-2 antigen induces mucosal immunity

A new study suggested that an intranasal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine induced mucosal immune responses in mice.

14 Sep 2022

SARS-CoV-2 viral infection is associated with an increased risk of Alzheimer’s disease

Older people who were infected with COVID-19 show a substantially higher risk - as much as 50% to 80% higher than a control group - of developing Alzheimer's disease within a year, according to a study of more than 6 million patients 65 and older.

14 Sep 2022

COVID-19 risk substantially reduced in seniors who receive 4th mRNA booster

In a recent study published in the Annals of Internal Medicine, researchers in Singapore estimated the effectiveness of the second booster (fourth dose) vaccination with messenger ribonucleic acid (mRNA) vaccines against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections with the SARS-CoV-2 Omicron variant and associated hospitalizations with among individuals aged ≥80 years.

14 Sep 2022

Parenteral-prime mucosal boost an effective strategy to protect against SARS-CoV-2

In a recent study published in the journal eBioMedicine, researchers in Denmark and Sweden administered a cationic liposome-adjuvanted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein subunit vaccine as a subcutaneous (s.c.) prime-intranasal (i.n.) boost strategy to elicit mucosal immune responses among SARS-CoV-2-infected Syrian hamsters.

14 Sep 2022

First-of-its-kind messenger RNA therapy developed for ovarian cancer, cachexia

Researchers at Oregon State University and Oregon Health & Science University have developed a promising, first-of-its-kind messenger RNA therapy for ovarian cancer as well as cachexia, a muscle-wasting condition associated with cancer and other chronic illnesses.

13 Sep 2022

Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancy

In an article published in the journal Expert Opinion on Drug Safety, scientists have described the safety and efficacy profiles of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies in pregnant women with coronavirus disease 2019 (COVID-19).

13 Sep 2022